Kromek Group Achieves First Profit, Driven by Landmark Siemens Agreement

Kromek Group plc ( (GB:KMK) ) just unveiled an update.

Kromek Group plc announced a significant financial turnaround for the year ending April 2025, achieving profitability for the first time and surpassing market expectations. This success was largely driven by a landmark agreement with Siemens Healthineers in the Advanced Imaging division, resulting in a substantial increase in revenue and a strengthened financial position. The company also made strategic advancements in its CBRN Detection division, securing contracts under UK Government frameworks and expanding its international sales pipeline. These developments position Kromek for continued growth and enhanced market competitiveness.

The most recent analyst rating on (GB:KMK) stock is a Hold with a £6.00 price target. To see the full list of analyst forecasts on Kromek Group plc stock, see the GB:KMK Stock Forecast page.

Spark’s Take on GB:KMK Stock

According to Spark, TipRanks’ AI Analyst, GB:KMK is a Neutral.

The overall score of 56 reflects a stock with moderate strengths and notable challenges. Positive corporate events and technical indicators provide optimism, but ongoing financial and profitability issues weigh heavily on the score.

To see Spark’s full report on GB:KMK stock, click here.

More about Kromek Group plc

Kromek Group plc is a leading developer of radiation and bio-detection technology solutions, focusing on advanced imaging and CBRN (Chemical, Biological, Radiological, and Nuclear) detection segments. The company is known for its work in medical imaging and nuclear security, with a strong emphasis on developing cadmium zinc telluride (CZT) detectors for high-resolution imaging applications.

Average Trading Volume: 1,331,053

Technical Sentiment Signal: Sell

Current Market Cap: £31.77M

For detailed information about KMK stock, go to TipRanks’ Stock Analysis page.